Gene therapy stocks in focus after Astellas/Audentes deal

Gene therapy stocks may see increased buying today in the wake of Astellas Pharma’s $60/share bid for Audentes Therapeutics.

Selected tickers: Editas Medicine (NASDAQ:EDIT) (+1%), Intellia Therapeutics (NASDAQ:NTLA) (+1%), CRISPR Therapeutics (NASDAQ:CRSP) (+1%), Orchard Therapeutics (NASDAQ:ORTX) (+11%), AVROBIO (NASDAQ:AVRO) (+3%), MeiraGTx Holdings (NASDAQ:MGTX) (+1%), bluebird bio (NASDAQ:BLUE) (+0.5%), Homology Medicines (NASDAQ:FIXX) (+4%), Solid Biosciences (NASDAQ:SLDB) (+4%), Abeona Therapeutics (NASDAQ:ABEO) (+10%), Capricor Therapeutics (NASDAQ:CAPR) (+4%), Sarepta Therapeutics (NASDAQ:SRPT) (+2%), BioMarin Pharmaceutical (NASDAQ:BMRN) (+2%), Voyager Therapeutics (NASDAQ:VYGR) (+5%), Sangamo Therapeutics (NASDAQ:SGMO) (+8%)

https://seekingalpha.com/news/3523311-gene-therapy-stocks-in-focus-after-astellas-audentes-deal